Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,17654464,flow rate,Components in the extract were separated on a 50 x 2.1 mm Aquasil C(18) 5 microm stainless steel column by isocratic elution with 40% acetonitrile/0.1% formic acid at a flow rate of 0.2 mL/min.,"A liquid chromatography/atmospheric pressure ionization tandem mass spectrometry quantitation method for nevirapine and its two oxidative metabolites, 2-hydroxynevirapine and nevirapine 4-carboxylic acid, and pharmacokinetics in baboons. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654464/),[ml] / [min],0.2,8046,DB01094,Hesperetin
,25785392,crystallite size,"HRN and mannitol were used in a 5:5 ratio, and an average crystallite size of HRN in NSD with mannitol was found to be 137.3 ± 90.0 nm.",Oral bioavailability and pharmacodynamic activity of hesperetin nanocrystals generated using a novel bottom-up technology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25785392/),nm,137.3,11544,DB01094,Hesperetin
,25785392,release rate enhancement,An in vitro release study revealed a statistically significant release rate enhancement for HRN nanocrystals (46.3 μg/mL/min) as compared to that of the control (29.5 μg/mL/min).,Oral bioavailability and pharmacodynamic activity of hesperetin nanocrystals generated using a novel bottom-up technology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25785392/),[μg] / [min·ml],46.3,11545,DB01094,Hesperetin
,25785392,release rate enhancement,An in vitro release study revealed a statistically significant release rate enhancement for HRN nanocrystals (46.3 μg/mL/min) as compared to that of the control (29.5 μg/mL/min).,Oral bioavailability and pharmacodynamic activity of hesperetin nanocrystals generated using a novel bottom-up technology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25785392/),[μg] / [min·ml],29.5,11546,DB01094,Hesperetin
,20184950,Ka,"Ka was 0.384+/-0.165 and 0.401+/-0.159, T(1/2(ke))(h) was 5.491+/-3.926 and 5.824+/-3.067, the AUC (mg/Lh) was 34.886+/-22.199 and 39.407+/-19.535 for naringenin and hesperetin, respectively.","Pharmacokinetics-based elucidation on disparity in clinical effectiveness between varieties of Zhi Zhu Wan, a Traditional Chinese Medical formula. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20184950/),,0.384,11784,DB01094,Hesperetin
,20184950,Ka,"Ka was 0.384+/-0.165 and 0.401+/-0.159, T(1/2(ke))(h) was 5.491+/-3.926 and 5.824+/-3.067, the AUC (mg/Lh) was 34.886+/-22.199 and 39.407+/-19.535 for naringenin and hesperetin, respectively.","Pharmacokinetics-based elucidation on disparity in clinical effectiveness between varieties of Zhi Zhu Wan, a Traditional Chinese Medical formula. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20184950/),,0.401,11785,DB01094,Hesperetin
,20184950,T(1/2(ke)),"Ka was 0.384+/-0.165 and 0.401+/-0.159, T(1/2(ke))(h) was 5.491+/-3.926 and 5.824+/-3.067, the AUC (mg/Lh) was 34.886+/-22.199 and 39.407+/-19.535 for naringenin and hesperetin, respectively.","Pharmacokinetics-based elucidation on disparity in clinical effectiveness between varieties of Zhi Zhu Wan, a Traditional Chinese Medical formula. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20184950/),h,5.491,11786,DB01094,Hesperetin
,20184950,T(1/2(ke)),"Ka was 0.384+/-0.165 and 0.401+/-0.159, T(1/2(ke))(h) was 5.491+/-3.926 and 5.824+/-3.067, the AUC (mg/Lh) was 34.886+/-22.199 and 39.407+/-19.535 for naringenin and hesperetin, respectively.","Pharmacokinetics-based elucidation on disparity in clinical effectiveness between varieties of Zhi Zhu Wan, a Traditional Chinese Medical formula. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20184950/),h,5.824,11787,DB01094,Hesperetin
,20184950,AUC,"Ka was 0.384+/-0.165 and 0.401+/-0.159, T(1/2(ke))(h) was 5.491+/-3.926 and 5.824+/-3.067, the AUC (mg/Lh) was 34.886+/-22.199 and 39.407+/-19.535 for naringenin and hesperetin, respectively.","Pharmacokinetics-based elucidation on disparity in clinical effectiveness between varieties of Zhi Zhu Wan, a Traditional Chinese Medical formula. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20184950/),[mg] / [lh],34.886,11788,DB01094,Hesperetin
,20184950,AUC,"Ka was 0.384+/-0.165 and 0.401+/-0.159, T(1/2(ke))(h) was 5.491+/-3.926 and 5.824+/-3.067, the AUC (mg/Lh) was 34.886+/-22.199 and 39.407+/-19.535 for naringenin and hesperetin, respectively.","Pharmacokinetics-based elucidation on disparity in clinical effectiveness between varieties of Zhi Zhu Wan, a Traditional Chinese Medical formula. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20184950/),[mg] / [lh],39.407,11789,DB01094,Hesperetin
,20184950,T(max),"T(max) for hesperetin in RZZW is about 8.515h, and its C(max) is much larger than that of BZZW.","Pharmacokinetics-based elucidation on disparity in clinical effectiveness between varieties of Zhi Zhu Wan, a Traditional Chinese Medical formula. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20184950/),h,8.515,11790,DB01094,Hesperetin
,18058792,half-lives,"Short half-lives (3-7 h) in serum were observed, while a better estimation of half-life (12-48 h) and the other pharmacokinetic parameters was observed using urinary data.","Pharmacokinetics of selected chiral flavonoids: hesperetin, naringenin and eriodictyol in rats and their content in fruit juices. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18058792/),h,3-7,16446,DB01094,Hesperetin
,18058792,half-life,"Short half-lives (3-7 h) in serum were observed, while a better estimation of half-life (12-48 h) and the other pharmacokinetic parameters was observed using urinary data.","Pharmacokinetics of selected chiral flavonoids: hesperetin, naringenin and eriodictyol in rats and their content in fruit juices. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18058792/),h,12-48,16447,DB01094,Hesperetin
,18058792,fe,"The three flavonoids are predominantly excreted via non-renal routes (fe values of 3-7%), and undergo rapid and extensive phase II metabolism.","Pharmacokinetics of selected chiral flavonoids: hesperetin, naringenin and eriodictyol in rats and their content in fruit juices. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18058792/),%,3-7,16448,DB01094,Hesperetin
,19007165,peak concentration (C(max)),"HPLC-MS(2) analysis revealed the accumulation of hesperetin-7-O-glucuronide, and an unassigned hesperetin-O-glucuronide metabolite in plasma reached a peak concentration (C(max)) of 924 +/- 224 nmol/L, 4.4 +/- 0.5 h (T(max)) after orange juice ingestion.",Bioavailability and metabolism of orange juice flavanones in humans: impact of a full-fat yogurt. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19007165/),[nM] / [l],924,26347,DB01094,Hesperetin
,19007165,T(max),"HPLC-MS(2) analysis revealed the accumulation of hesperetin-7-O-glucuronide, and an unassigned hesperetin-O-glucuronide metabolite in plasma reached a peak concentration (C(max)) of 924 +/- 224 nmol/L, 4.4 +/- 0.5 h (T(max)) after orange juice ingestion.",Bioavailability and metabolism of orange juice flavanones in humans: impact of a full-fat yogurt. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19007165/),h,4.4,26348,DB01094,Hesperetin
,19007165,C(max),"When the juice was consumed with yogurt, neither the C(max) at 661 +/- 170 nmol/L nor the T(max) at 5.1 +/- 0.4 h were significantly different from those obtained with juice alone.",Bioavailability and metabolism of orange juice flavanones in humans: impact of a full-fat yogurt. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19007165/),[nM] / [l],661,26349,DB01094,Hesperetin
,19007165,T(max),"When the juice was consumed with yogurt, neither the C(max) at 661 +/- 170 nmol/L nor the T(max) at 5.1 +/- 0.4 h were significantly different from those obtained with juice alone.",Bioavailability and metabolism of orange juice flavanones in humans: impact of a full-fat yogurt. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19007165/),h,5.1,26350,DB01094,Hesperetin
,19083501,plasma concentrations,Mean plasma concentrations ranged from 7.8 to 11.8 mumol/L.,Mangiferin and hesperidin metabolites are absorbed from the gastrointestinal tract of pigs after oral ingestion of a Cyclopia genistoides (honeybush tea) extract. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19083501/),[μM] / [l],7.8 to 11.8,49347,DB01094,Hesperetin
,16424119,area under the curve (AUC),"The area under the curve (AUC) for total plasma hesperetin of subjects consuming hesperetin-7-glucoside juice was 2-fold higher than that of subjects consuming the ""low"" dose hesperidin juice [3.45+/-1.27 vs. 1.16+/-0.52 mmol/(L.h), respectively, P>0.0001].","Bioavailability is improved by enzymatic modification of the citrus flavonoid hesperidin in humans: a randomized, double-blind, crossover trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16424119/),[mM] / [h·l],3.45,60374,DB01094,Hesperetin
,16424119,area under the curve (AUC),"The area under the curve (AUC) for total plasma hesperetin of subjects consuming hesperetin-7-glucoside juice was 2-fold higher than that of subjects consuming the ""low"" dose hesperidin juice [3.45+/-1.27 vs. 1.16+/-0.52 mmol/(L.h), respectively, P>0.0001].","Bioavailability is improved by enzymatic modification of the citrus flavonoid hesperidin in humans: a randomized, double-blind, crossover trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16424119/),[mM] / [h·l],1.16,60375,DB01094,Hesperetin
,16424119,AUC,"The AUC for hesperetin after consuming the hesperetin-7-glucoside juice was improved to the level of the ""high"" dose hesperidin juice [4.16+/-1.50 mmol/(L.h)].","Bioavailability is improved by enzymatic modification of the citrus flavonoid hesperidin in humans: a randomized, double-blind, crossover trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16424119/),[mM] / [h·l],4.16,60376,DB01094,Hesperetin
,16424119,peak plasma concentrations (C(max)),"The peak plasma concentrations (C(max)) of hesperetin were 4-fold higher (2.60+/-1.07 mmol/L, P<0.0001) after subjects consumed hesperetin-7-glucoside juice compared with those consuming ""low"" dose hesperidin juice (0.48 +/- 0.27 mmol/L), and 1.5-fold higher than those consuming ""high"" dose hesperidin juice (1.05+/-0.25 mmol/L).","Bioavailability is improved by enzymatic modification of the citrus flavonoid hesperidin in humans: a randomized, double-blind, crossover trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16424119/),[mM] / [l],2.60,60377,DB01094,Hesperetin
,16424119,peak plasma concentrations (C(max)),"The peak plasma concentrations (C(max)) of hesperetin were 4-fold higher (2.60+/-1.07 mmol/L, P<0.0001) after subjects consumed hesperetin-7-glucoside juice compared with those consuming ""low"" dose hesperidin juice (0.48 +/- 0.27 mmol/L), and 1.5-fold higher than those consuming ""high"" dose hesperidin juice (1.05+/-0.25 mmol/L).","Bioavailability is improved by enzymatic modification of the citrus flavonoid hesperidin in humans: a randomized, double-blind, crossover trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16424119/),[mM] / [l],0.48,60378,DB01094,Hesperetin
,16424119,peak plasma concentrations (C(max)),"The peak plasma concentrations (C(max)) of hesperetin were 4-fold higher (2.60+/-1.07 mmol/L, P<0.0001) after subjects consumed hesperetin-7-glucoside juice compared with those consuming ""low"" dose hesperidin juice (0.48 +/- 0.27 mmol/L), and 1.5-fold higher than those consuming ""high"" dose hesperidin juice (1.05+/-0.25 mmol/L).","Bioavailability is improved by enzymatic modification of the citrus flavonoid hesperidin in humans: a randomized, double-blind, crossover trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16424119/),[mM] / [l],1.05,60379,DB01094,Hesperetin
,16424119,T(max),"The corresponding T(max) was much faster (0.6+/-0.1 h, P<0.0001) after subjects consumed hesperetin-7-glucoside juice compared with ""low"" dose (7.0+/-3.0 h) and ""high"" dose (7.4+/-2.0 h) hesperidin juices.","Bioavailability is improved by enzymatic modification of the citrus flavonoid hesperidin in humans: a randomized, double-blind, crossover trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16424119/),h,0.6,60380,DB01094,Hesperetin
,16424119,T(max),"The corresponding T(max) was much faster (0.6+/-0.1 h, P<0.0001) after subjects consumed hesperetin-7-glucoside juice compared with ""low"" dose (7.0+/-3.0 h) and ""high"" dose (7.4+/-2.0 h) hesperidin juices.","Bioavailability is improved by enzymatic modification of the citrus flavonoid hesperidin in humans: a randomized, double-blind, crossover trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16424119/),h,7.0,60381,DB01094,Hesperetin
,16424119,T(max),"The corresponding T(max) was much faster (0.6+/-0.1 h, P<0.0001) after subjects consumed hesperetin-7-glucoside juice compared with ""low"" dose (7.0+/-3.0 h) and ""high"" dose (7.4+/-2.0 h) hesperidin juices.","Bioavailability is improved by enzymatic modification of the citrus flavonoid hesperidin in humans: a randomized, double-blind, crossover trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16424119/),h,7.4,60382,DB01094,Hesperetin
,25276981,flow rate,"Plasma samples were separated on a C18 column (4.6 mm x 150 mm, 5 microm), using 0.1% phosphoric acid and methanol as mobile phase at a flow rate of 1.0 mL x min(-1) with gradient elution.",[Effect of different compatibility of zhizi dahuang decoction on pharmacokinetics of naringenin and hesperetin]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25276981/),[ml] / [min],1.0,66132,DB01094,Hesperetin
,17047689,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) for hesperetin and naringenin were 825.78+/-410.63 ng/ml (2731.8+/-1358.4 nmol/l) and 2009.51+/-770.82 ng/ml (7386.6+/-2833.4 nmol/l), respectively and the mean AUC(0-infinity) values were 4846.20+/-1675.99 ng h/ml and 9424.52+/-2960.52 ng h/ml for hesperetin and naringenin, respectively.",Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17047689/),[ng] / [ml],825.78,66968,DB01094,Hesperetin
,17047689,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) for hesperetin and naringenin were 825.78+/-410.63 ng/ml (2731.8+/-1358.4 nmol/l) and 2009.51+/-770.82 ng/ml (7386.6+/-2833.4 nmol/l), respectively and the mean AUC(0-infinity) values were 4846.20+/-1675.99 ng h/ml and 9424.52+/-2960.52 ng h/ml for hesperetin and naringenin, respectively.",Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17047689/),[nM] / [l],2731.8,66969,DB01094,Hesperetin
,17047689,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) for hesperetin and naringenin were 825.78+/-410.63 ng/ml (2731.8+/-1358.4 nmol/l) and 2009.51+/-770.82 ng/ml (7386.6+/-2833.4 nmol/l), respectively and the mean AUC(0-infinity) values were 4846.20+/-1675.99 ng h/ml and 9424.52+/-2960.52 ng h/ml for hesperetin and naringenin, respectively.",Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17047689/),[ng] / [ml],2009.51,66970,DB01094,Hesperetin
,17047689,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) for hesperetin and naringenin were 825.78+/-410.63 ng/ml (2731.8+/-1358.4 nmol/l) and 2009.51+/-770.82 ng/ml (7386.6+/-2833.4 nmol/l), respectively and the mean AUC(0-infinity) values were 4846.20+/-1675.99 ng h/ml and 9424.52+/-2960.52 ng h/ml for hesperetin and naringenin, respectively.",Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17047689/),[nM] / [l],7386.6,66971,DB01094,Hesperetin
,17047689,AUC(0-infinity),"The mean peak plasma concentration (C(max)) for hesperetin and naringenin were 825.78+/-410.63 ng/ml (2731.8+/-1358.4 nmol/l) and 2009.51+/-770.82 ng/ml (7386.6+/-2833.4 nmol/l), respectively and the mean AUC(0-infinity) values were 4846.20+/-1675.99 ng h/ml and 9424.52+/-2960.52 ng h/ml for hesperetin and naringenin, respectively.",Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17047689/),[h·ng] / [ml],4846.20,66972,DB01094,Hesperetin
,17047689,AUC(0-infinity),"The mean peak plasma concentration (C(max)) for hesperetin and naringenin were 825.78+/-410.63 ng/ml (2731.8+/-1358.4 nmol/l) and 2009.51+/-770.82 ng/ml (7386.6+/-2833.4 nmol/l), respectively and the mean AUC(0-infinity) values were 4846.20+/-1675.99 ng h/ml and 9424.52+/-2960.52 ng h/ml for hesperetin and naringenin, respectively.",Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17047689/),[h·ng] / [ml],9424.52,66973,DB01094,Hesperetin
,17047689,elimination half-life,"The elimination half-life for hesperetin was found to be 3.05+/-0.91 h and for naringenin 2.31+/-0.40 h, respectively.",Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17047689/),h,3.05,66974,DB01094,Hesperetin
,17047689,elimination half-life,"The elimination half-life for hesperetin was found to be 3.05+/-0.91 h and for naringenin 2.31+/-0.40 h, respectively.",Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17047689/),h,2.31,66975,DB01094,Hesperetin
,17047689,relative cumulative urinary excretion,"The mean values of the relative cumulative urinary excretion, as percentage of the administered dose, for hesperetin and naringenin, were found to be 3.26+/-0.44 and 5.81+/-0.81%, respectively.",Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17047689/),%,3.26,66976,DB01094,Hesperetin
,17047689,relative cumulative urinary excretion,"The mean values of the relative cumulative urinary excretion, as percentage of the administered dose, for hesperetin and naringenin, were found to be 3.26+/-0.44 and 5.81+/-0.81%, respectively.",Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17047689/),%,5.81,66977,DB01094,Hesperetin
,33533607,half-lives,"The half-lives of the metabolites in plasma were between 3 and 3.2 h, and the total bioavailability of eriocitrin was less than 1%.",Pharmacokinetics and Biodistribution of Eriocitrin in Rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33533607/),h,3 and 3.2,68062,DB01094,Hesperetin
less,33533607,total bioavailability,"The half-lives of the metabolites in plasma were between 3 and 3.2 h, and the total bioavailability of eriocitrin was less than 1%.",Pharmacokinetics and Biodistribution of Eriocitrin in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33533607/),%,1,68063,DB01094,Hesperetin
,23148023,total run time,"Biosamples were prepared using methanolic precipitation, and the separation of hesperetin and naringenin was achieved on a Waters ACQUITY HSS BEH (2.1 mm × 5 mm, 1.7 µm) column by linear gradient elution, and the total run time was only 3 min.","Pharmacokinetics of hesperetin and naringenin in the Zhi Zhu Wan, a traditional Chinese medicinal formulae, and its pharmacodynamics study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23148023/),min,3,69757,DB01094,Hesperetin
,23148023,C(max),"With pharmacokinetic analysis, the estimated pharmacokinetic parameters (i.e. C(max), area under the concentration-time curve (AUC) and t(1/2)), were C(max) = 776.06 ng/mL, AUC = 9473 ng/mL·h, t1/2 = 5.26 h for hesperetin and C(max) = 2910.6 ng/mL, AUC = 40607.9 ng/mL·h, t1/2 = 4.69 h for naringenin, respectively.","Pharmacokinetics of hesperetin and naringenin in the Zhi Zhu Wan, a traditional Chinese medicinal formulae, and its pharmacodynamics study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23148023/),[ng] / [ml],776.06,69758,DB01094,Hesperetin
,23148023,AUC,"With pharmacokinetic analysis, the estimated pharmacokinetic parameters (i.e. C(max), area under the concentration-time curve (AUC) and t(1/2)), were C(max) = 776.06 ng/mL, AUC = 9473 ng/mL·h, t1/2 = 5.26 h for hesperetin and C(max) = 2910.6 ng/mL, AUC = 40607.9 ng/mL·h, t1/2 = 4.69 h for naringenin, respectively.","Pharmacokinetics of hesperetin and naringenin in the Zhi Zhu Wan, a traditional Chinese medicinal formulae, and its pharmacodynamics study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23148023/),[ng] / [h·ml],9473,69759,DB01094,Hesperetin
,23148023,t1/2,"With pharmacokinetic analysis, the estimated pharmacokinetic parameters (i.e. C(max), area under the concentration-time curve (AUC) and t(1/2)), were C(max) = 776.06 ng/mL, AUC = 9473 ng/mL·h, t1/2 = 5.26 h for hesperetin and C(max) = 2910.6 ng/mL, AUC = 40607.9 ng/mL·h, t1/2 = 4.69 h for naringenin, respectively.","Pharmacokinetics of hesperetin and naringenin in the Zhi Zhu Wan, a traditional Chinese medicinal formulae, and its pharmacodynamics study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23148023/),h,5.26,69760,DB01094,Hesperetin
,23148023,C(max),"With pharmacokinetic analysis, the estimated pharmacokinetic parameters (i.e. C(max), area under the concentration-time curve (AUC) and t(1/2)), were C(max) = 776.06 ng/mL, AUC = 9473 ng/mL·h, t1/2 = 5.26 h for hesperetin and C(max) = 2910.6 ng/mL, AUC = 40607.9 ng/mL·h, t1/2 = 4.69 h for naringenin, respectively.","Pharmacokinetics of hesperetin and naringenin in the Zhi Zhu Wan, a traditional Chinese medicinal formulae, and its pharmacodynamics study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23148023/),[ng] / [ml],2910.6,69761,DB01094,Hesperetin
,23148023,AUC,"With pharmacokinetic analysis, the estimated pharmacokinetic parameters (i.e. C(max), area under the concentration-time curve (AUC) and t(1/2)), were C(max) = 776.06 ng/mL, AUC = 9473 ng/mL·h, t1/2 = 5.26 h for hesperetin and C(max) = 2910.6 ng/mL, AUC = 40607.9 ng/mL·h, t1/2 = 4.69 h for naringenin, respectively.","Pharmacokinetics of hesperetin and naringenin in the Zhi Zhu Wan, a traditional Chinese medicinal formulae, and its pharmacodynamics study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23148023/),[ng] / [h·ml],40607.9,69762,DB01094,Hesperetin
,23148023,t1/2,"With pharmacokinetic analysis, the estimated pharmacokinetic parameters (i.e. C(max), area under the concentration-time curve (AUC) and t(1/2)), were C(max) = 776.06 ng/mL, AUC = 9473 ng/mL·h, t1/2 = 5.26 h for hesperetin and C(max) = 2910.6 ng/mL, AUC = 40607.9 ng/mL·h, t1/2 = 4.69 h for naringenin, respectively.","Pharmacokinetics of hesperetin and naringenin in the Zhi Zhu Wan, a traditional Chinese medicinal formulae, and its pharmacodynamics study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23148023/),h,4.69,69763,DB01094,Hesperetin
,24255025,Urinary excretion,Urinary excretion of four hesperetin glucuronides was equivalent to 0.28% of intake while that of the two naringenin glucuronides was 2.8% of intake.,"Absorption, metabolism, and excretion of fermented orange juice (poly)phenols in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24255025/),%,0.28,102337,DB01094,Hesperetin
,24255025,Urinary excretion,Urinary excretion of four hesperetin glucuronides was equivalent to 0.28% of intake while that of the two naringenin glucuronides was 2.8% of intake.,"Absorption, metabolism, and excretion of fermented orange juice (poly)phenols in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24255025/),%,2.8,102338,DB01094,Hesperetin
,30553062,particle size (Zavg),The optimized NSD formulation showed an average particle size (Zavg) of 558.2 ± 68.1 nm and ~70% release in 30 min.,"Nanocrystalline solid dispersions (NSD) of hesperetin (HRN) for prevention of 7, 12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in Sprague-Dawley (SD) rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30553062/),nm,558.2,102464,DB01094,Hesperetin
,30829014,peak plasma concentration (Cmax),"Importantly, the in vivo oral absorption study on rats indicated that the micelles and complexes significantly increased the peak plasma concentration (Cmax) from 2.64 μg/mL to 20.67 and 33.09 μg/mL and also increased the area under the concentration-time curve of hesperetin after oral administration to 16.2- and 18.0-fold, respectively.","Enhanced water solubility, antioxidant activity, and oral absorption of hesperetin by D-α-tocopheryl polyethylene glycol 1000 succinate and phosphatidylcholine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30829014/),[μg] / [ml],2.64,105518,DB01094,Hesperetin
,30829014,peak plasma concentration (Cmax),"Importantly, the in vivo oral absorption study on rats indicated that the micelles and complexes significantly increased the peak plasma concentration (Cmax) from 2.64 μg/mL to 20.67 and 33.09 μg/mL and also increased the area under the concentration-time curve of hesperetin after oral administration to 16.2- and 18.0-fold, respectively.","Enhanced water solubility, antioxidant activity, and oral absorption of hesperetin by D-α-tocopheryl polyethylene glycol 1000 succinate and phosphatidylcholine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30829014/),[μg] / [ml],20.67,105519,DB01094,Hesperetin
,30829014,peak plasma concentration (Cmax),"Importantly, the in vivo oral absorption study on rats indicated that the micelles and complexes significantly increased the peak plasma concentration (Cmax) from 2.64 μg/mL to 20.67 and 33.09 μg/mL and also increased the area under the concentration-time curve of hesperetin after oral administration to 16.2- and 18.0-fold, respectively.","Enhanced water solubility, antioxidant activity, and oral absorption of hesperetin by D-α-tocopheryl polyethylene glycol 1000 succinate and phosphatidylcholine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30829014/),[μg] / [ml],33.09,105520,DB01094,Hesperetin
,32636752,Tmax,"Meranzin hydrate and meranzin (coumarins) were absorbed rapidly (Tmax, about 1.0 h) but eliminated slowly (t1/2z exceeds 6.5 h).","Multi-Component Comparative Pharmacokinetics in Rats After Oral Administration of Fructus aurantii Extract, Naringin, Neohesperidin, and Naringin-Neohesperidin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32636752/),h,1.0,106771,DB01094,Hesperetin
exceeds,32636752,t1/2z,"Meranzin hydrate and meranzin (coumarins) were absorbed rapidly (Tmax, about 1.0 h) but eliminated slowly (t1/2z exceeds 6.5 h).","Multi-Component Comparative Pharmacokinetics in Rats After Oral Administration of Fructus aurantii Extract, Naringin, Neohesperidin, and Naringin-Neohesperidin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32636752/),h,6.5,106772,DB01094,Hesperetin
,28284083,flow rate,"Sample preparation was accomplished through protein precipitation, and chromatographic separation was achieved on an Agilent Zorbax Extend C18 column with a security guard cartridge C8 using a binary gradient with mobile phase A (water/0.1% formic acid) and B (ACN/0.1% formic acid) at a flow rate of 400μl/min.",Plasma pharmacokinetics and bioavailability of verticillin A following different routes of administration in mice using liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28284083/),[μl] / [min],400,114240,DB01094,Hesperetin
,28284083,total chromatographic run time,"The total chromatographic run time was 8min, and the assay was linear in the concentration range of 1-1000nM.",Plasma pharmacokinetics and bioavailability of verticillin A following different routes of administration in mice using liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28284083/),min,8,114241,DB01094,Hesperetin
,28284083,Cmax,It was found that intraperitoneal dosing of 3mg/kg resulted in high systemic exposure and achieved Cmax of 110nM with plasma concentrations sustained above 10nM for the 24-h duration of the study.,Plasma pharmacokinetics and bioavailability of verticillin A following different routes of administration in mice using liquid chromatography tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28284083/),nM,110,114242,DB01094,Hesperetin
,28284083,Cmax,"Intravenous and oral dosing achieved observed Cmax of 73nM and 9nM, respectively.",Plasma pharmacokinetics and bioavailability of verticillin A following different routes of administration in mice using liquid chromatography tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28284083/),nM,73,114243,DB01094,Hesperetin
,28284083,Cmax,"Intravenous and oral dosing achieved observed Cmax of 73nM and 9nM, respectively.",Plasma pharmacokinetics and bioavailability of verticillin A following different routes of administration in mice using liquid chromatography tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28284083/),nM,9,114244,DB01094,Hesperetin
,28284083,bioavailability,Oral dosing resulted in an approximate 9% bioavailability.,Plasma pharmacokinetics and bioavailability of verticillin A following different routes of administration in mice using liquid chromatography tandem mass spectrometry. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28284083/),%,9,114245,DB01094,Hesperetin
,28820428,Tmax,Glucosamine was detected up to 8 h post-dose with a Tmax of 2 h and Cmax of 9.69 μg/mL.,Pharmacokinetic Analysis of an Oral Multicomponent Joint Dietary Supplement (Phycox®) in Dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28820428/),h,2,120987,DB01094,Hesperetin
,28820428,Cmax,Glucosamine was detected up to 8 h post-dose with a Tmax of 2 h and Cmax of 9.69 μg/mL.,Pharmacokinetic Analysis of an Oral Multicomponent Joint Dietary Supplement (Phycox®) in Dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28820428/),[μg] / [ml],9.69,120988,DB01094,Hesperetin
,26551533,flow rate,"Chromatographic separation was achieved on a Phenomenex Luna C18 column (150 × 4.6mm, 3 μm), using isocratic mobile phase consisting of 0.1% formic acid-acetonitrile (50:50, v/v) at a flow rate of 300 μl/min.","A HPLC-MS/MS method for the quantitation of free, conjugated, and total HDND-7, a novel hesperetin derivative, in rat plasma and tissues: Application to the pharmacokinetic and tissue distribution study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26551533/),[μl] / [min],300,124286,DB01094,Hesperetin
,26551533,run time,The detection was performed on a triple quadruple tandem mass spectrometer using positive electrospray ionization (ESI) source with a chromatographic run time of 5.0 min.,"A HPLC-MS/MS method for the quantitation of free, conjugated, and total HDND-7, a novel hesperetin derivative, in rat plasma and tissues: Application to the pharmacokinetic and tissue distribution study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26551533/),min,5.0,124287,DB01094,Hesperetin
,26551533,m/z,"The detection was operated by multiple reaction monitoring (MRM) of the transitions of m/z 429.3 → 223.9 for HDND-7 and 272.9 → 152.9 for naringenin (IS), respectively.","A HPLC-MS/MS method for the quantitation of free, conjugated, and total HDND-7, a novel hesperetin derivative, in rat plasma and tissues: Application to the pharmacokinetic and tissue distribution study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26551533/),,429.3,124288,DB01094,Hesperetin
,26551533,m/z,"The detection was operated by multiple reaction monitoring (MRM) of the transitions of m/z 429.3 → 223.9 for HDND-7 and 272.9 → 152.9 for naringenin (IS), respectively.","A HPLC-MS/MS method for the quantitation of free, conjugated, and total HDND-7, a novel hesperetin derivative, in rat plasma and tissues: Application to the pharmacokinetic and tissue distribution study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26551533/),,223.9,124289,DB01094,Hesperetin
,26551533,m/z,"The detection was operated by multiple reaction monitoring (MRM) of the transitions of m/z 429.3 → 223.9 for HDND-7 and 272.9 → 152.9 for naringenin (IS), respectively.","A HPLC-MS/MS method for the quantitation of free, conjugated, and total HDND-7, a novel hesperetin derivative, in rat plasma and tissues: Application to the pharmacokinetic and tissue distribution study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26551533/),,272.9,124290,DB01094,Hesperetin
,26551533,m/z,"The detection was operated by multiple reaction monitoring (MRM) of the transitions of m/z 429.3 → 223.9 for HDND-7 and 272.9 → 152.9 for naringenin (IS), respectively.","A HPLC-MS/MS method for the quantitation of free, conjugated, and total HDND-7, a novel hesperetin derivative, in rat plasma and tissues: Application to the pharmacokinetic and tissue distribution study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26551533/),,152.9,124291,DB01094,Hesperetin
,26551533,extraction recoveries,"Mean extraction recoveries in plasma and tissues ranged from 87.4 to 97.1% and from 54.2 to 70.5%, respectively.","A HPLC-MS/MS method for the quantitation of free, conjugated, and total HDND-7, a novel hesperetin derivative, in rat plasma and tissues: Application to the pharmacokinetic and tissue distribution study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26551533/),%,87.4 to 97.1,124292,DB01094,Hesperetin
,26551533,extraction recoveries,"Mean extraction recoveries in plasma and tissues ranged from 87.4 to 97.1% and from 54.2 to 70.5%, respectively.","A HPLC-MS/MS method for the quantitation of free, conjugated, and total HDND-7, a novel hesperetin derivative, in rat plasma and tissues: Application to the pharmacokinetic and tissue distribution study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26551533/),%,54.2 to 70.5,124293,DB01094,Hesperetin
,27175336,absolute oral bioavailability,"The absolute oral bioavailability of Rs-1 was 2.3%, and the total absorption rose to 31.5% with addition of its glucuronide and sulfate metabolites.","Pharmacokinetics, bioavailability, metabolism and excretion of δ-viniferin in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27175336/),%,2.3,142167,DB01094,Hesperetin
,27175336,total absorption,"The absolute oral bioavailability of Rs-1 was 2.3%, and the total absorption rose to 31.5% with addition of its glucuronide and sulfate metabolites.","Pharmacokinetics, bioavailability, metabolism and excretion of δ-viniferin in rats. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27175336/),%,31.5,142168,DB01094,Hesperetin
,20954071,maximal concentration (C(max)),"The maximal concentration (C(max)) values of hesperetin in non-antibiotic-exposed and pseudo-germ-free rats were 0.58 and 0.20 μg/ml, respectively, and area under the curve (AUC) values were 6.3 and 2.8 μg-h/ml, respectively.",Effects of gut microflora on pharmacokinetics of hesperidin: a study on non-antibiotic and pseudo-germ-free rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954071/),[μg] / [ml],0.58,164199,DB01094,Hesperetin
,20954071,maximal concentration (C(max)),"The maximal concentration (C(max)) values of hesperetin in non-antibiotic-exposed and pseudo-germ-free rats were 0.58 and 0.20 μg/ml, respectively, and area under the curve (AUC) values were 6.3 and 2.8 μg-h/ml, respectively.",Effects of gut microflora on pharmacokinetics of hesperidin: a study on non-antibiotic and pseudo-germ-free rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954071/),[μg] / [ml],0.20,164200,DB01094,Hesperetin
,20954071,area under the curve (AUC),"The maximal concentration (C(max)) values of hesperetin in non-antibiotic-exposed and pseudo-germ-free rats were 0.58 and 0.20 μg/ml, respectively, and area under the curve (AUC) values were 6.3 and 2.8 μg-h/ml, respectively.",Effects of gut microflora on pharmacokinetics of hesperidin: a study on non-antibiotic and pseudo-germ-free rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954071/),[μg-h] / [ml],6.3,164201,DB01094,Hesperetin
,20954071,area under the curve (AUC),"The maximal concentration (C(max)) values of hesperetin in non-antibiotic-exposed and pseudo-germ-free rats were 0.58 and 0.20 μg/ml, respectively, and area under the curve (AUC) values were 6.3 and 2.8 μg-h/ml, respectively.",Effects of gut microflora on pharmacokinetics of hesperidin: a study on non-antibiotic and pseudo-germ-free rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954071/),[μg-h] / [ml],2.8,164202,DB01094,Hesperetin
,20954071,β-,"Fecal β-glucosidase activities of non-antibiotic-exposed and pseudo-germ-free rats were 0.21 and 0.11 nmol/min/mg, while fecal α-rhamnosidase activities were 0.37 and 0.12 nmol/min/mg, respectively.",Effects of gut microflora on pharmacokinetics of hesperidin: a study on non-antibiotic and pseudo-germ-free rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954071/),[nM] / [mg·min],0.21,164203,DB01094,Hesperetin
,20954071,activities,"Fecal β-glucosidase activities of non-antibiotic-exposed and pseudo-germ-free rats were 0.21 and 0.11 nmol/min/mg, while fecal α-rhamnosidase activities were 0.37 and 0.12 nmol/min/mg, respectively.",Effects of gut microflora on pharmacokinetics of hesperidin: a study on non-antibiotic and pseudo-germ-free rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954071/),[nM] / [mg·min],0.21,164204,DB01094,Hesperetin
,20954071,activities,"Fecal β-glucosidase activities of non-antibiotic-exposed and pseudo-germ-free rats were 0.21 and 0.11 nmol/min/mg, while fecal α-rhamnosidase activities were 0.37 and 0.12 nmol/min/mg, respectively.",Effects of gut microflora on pharmacokinetics of hesperidin: a study on non-antibiotic and pseudo-germ-free rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954071/),[nM] / [mg·min],0.11,164205,DB01094,Hesperetin
,20954071,idas,"Fecal β-glucosidase activities of non-antibiotic-exposed and pseudo-germ-free rats were 0.21 and 0.11 nmol/min/mg, while fecal α-rhamnosidase activities were 0.37 and 0.12 nmol/min/mg, respectively.",Effects of gut microflora on pharmacokinetics of hesperidin: a study on non-antibiotic and pseudo-germ-free rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954071/),[nM] / [mg·min],0.37,164206,DB01094,Hesperetin
,20954071,idas,"Fecal β-glucosidase activities of non-antibiotic-exposed and pseudo-germ-free rats were 0.21 and 0.11 nmol/min/mg, while fecal α-rhamnosidase activities were 0.37 and 0.12 nmol/min/mg, respectively.",Effects of gut microflora on pharmacokinetics of hesperidin: a study on non-antibiotic and pseudo-germ-free rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954071/),[nM] / [mg·min],0.12,164207,DB01094,Hesperetin
,20954071,activities,"Fecal β-glucosidase activities of non-antibiotic-exposed and pseudo-germ-free rats were 0.21 and 0.11 nmol/min/mg, while fecal α-rhamnosidase activities were 0.37 and 0.12 nmol/min/mg, respectively.",Effects of gut microflora on pharmacokinetics of hesperidin: a study on non-antibiotic and pseudo-germ-free rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954071/),[nM] / [mg·min],0.37,164208,DB01094,Hesperetin
,20954071,activities,"Fecal β-glucosidase activities of non-antibiotic-exposed and pseudo-germ-free rats were 0.21 and 0.11 nmol/min/mg, while fecal α-rhamnosidase activities were 0.37 and 0.12 nmol/min/mg, respectively.",Effects of gut microflora on pharmacokinetics of hesperidin: a study on non-antibiotic and pseudo-germ-free rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954071/),[nM] / [mg·min],0.12,164209,DB01094,Hesperetin
,20954071,rate of he,"The rate of hesperidin transformation to hesperetin was 6.9 and 2.9 nmol/min/g in fecal samples in non-antibiotic-exposed and pseudo-germ-free rats, respectively.",Effects of gut microflora on pharmacokinetics of hesperidin: a study on non-antibiotic and pseudo-germ-free rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954071/),[nM] / [g·min],6.9,164210,DB01094,Hesperetin
,20954071,rate of he,"The rate of hesperidin transformation to hesperetin was 6.9 and 2.9 nmol/min/g in fecal samples in non-antibiotic-exposed and pseudo-germ-free rats, respectively.",Effects of gut microflora on pharmacokinetics of hesperidin: a study on non-antibiotic and pseudo-germ-free rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954071/),[nM] / [g·min],2.9,164211,DB01094,Hesperetin
,11160539,peak plasma concentrations (C(max)),"The resulting plasma concentrations were comparatively high, and the peak plasma concentrations (C(max)) were 0.6 +/- 0.4 micromol/L (means +/- SD) for naringenin from orange juice and 6.0 +/- 5.4 micromol/L for naringenin from grapefruit juice.",Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11160539/),[μM] / [l],0.6,172800,DB01094,Hesperetin
,11160539,peak plasma concentrations (C(max)),"The resulting plasma concentrations were comparatively high, and the peak plasma concentrations (C(max)) were 0.6 +/- 0.4 micromol/L (means +/- SD) for naringenin from orange juice and 6.0 +/- 5.4 micromol/L for naringenin from grapefruit juice.",Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11160539/),[μM] / [l],6.0,172801,DB01094,Hesperetin
,11160539,elimination half-lives,"The elimination half-lives were between 1.3 and 2.2 h, and therefore plasma concentrations reflect short-term intake.",Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11160539/),h,1.3 and 2.2,172802,DB01094,Hesperetin
,11160539,relative urinary excretion,"The relative urinary excretion varied depending on the flavanone source and dose and was 30.2 +/- 25.5% and 1.1 +/- 0.8% for naringenin from grapefruit juice and orange juice, respectively, and 5.3 +/- 3.1% for hesperetin from orange juice.",Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11160539/),%,30.2,172803,DB01094,Hesperetin
,11160539,relative urinary excretion,"The relative urinary excretion varied depending on the flavanone source and dose and was 30.2 +/- 25.5% and 1.1 +/- 0.8% for naringenin from grapefruit juice and orange juice, respectively, and 5.3 +/- 3.1% for hesperetin from orange juice.",Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11160539/),%,1.1,172804,DB01094,Hesperetin
,11160539,relative urinary excretion,"The relative urinary excretion varied depending on the flavanone source and dose and was 30.2 +/- 25.5% and 1.1 +/- 0.8% for naringenin from grapefruit juice and orange juice, respectively, and 5.3 +/- 3.1% for hesperetin from orange juice.",Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11160539/),%,5.3,172805,DB01094,Hesperetin
,30286676,Cmax,"Analysis of the clinical PK parameters, calculated using a one-compartment model, showed that the Cmax parameters of LNH in 3, 4 and 4 h were 639.17, 410.00 and 181.67 μg/L, respectively.","Pharmacokinetic study of the prokinetic ABCs liquiritigenin, naringenin and hesperitin following the oral administration of Si-Ni-San decoction to functional dyspepsia patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30286676/),[μg] / [l],639.17,186272,DB01094,Hesperetin
,30286676,Cmax,"Analysis of the clinical PK parameters, calculated using a one-compartment model, showed that the Cmax parameters of LNH in 3, 4 and 4 h were 639.17, 410.00 and 181.67 μg/L, respectively.","Pharmacokinetic study of the prokinetic ABCs liquiritigenin, naringenin and hesperitin following the oral administration of Si-Ni-San decoction to functional dyspepsia patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30286676/),[μg] / [l],410.00,186273,DB01094,Hesperetin
,30286676,Cmax,"Analysis of the clinical PK parameters, calculated using a one-compartment model, showed that the Cmax parameters of LNH in 3, 4 and 4 h were 639.17, 410.00 and 181.67 μg/L, respectively.","Pharmacokinetic study of the prokinetic ABCs liquiritigenin, naringenin and hesperitin following the oral administration of Si-Ni-San decoction to functional dyspepsia patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30286676/),[μg] / [l],181.67,186274,DB01094,Hesperetin
,33799874,Tmax,Total plasma metabolites showed significantly mean lower Tmax (6.0 ± 0.4 vs. 8.0 ± 0.5 h) and higher Cmax and AUC values after lemon extract intake.,New Insights into the Metabolism of the Flavanones Eriocitrin and Hesperidin: A Comparative Human Pharmacokinetic Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33799874/),h,6.0,197768,DB01094,Hesperetin
,33799874,Tmax,Total plasma metabolites showed significantly mean lower Tmax (6.0 ± 0.4 vs. 8.0 ± 0.5 h) and higher Cmax and AUC values after lemon extract intake.,New Insights into the Metabolism of the Flavanones Eriocitrin and Hesperidin: A Comparative Human Pharmacokinetic Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33799874/),h,8.0,197769,DB01094,Hesperetin
,18384064,recoveries,"The recoveries of naringenin and hesperetin were 72.8-76.6 and 75.7-77.2%, respectively.",Simultaneous determination of naringenin and hesperetin in rats after oral administration of Da-Cheng-Qi decoction by high-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18384064/),%,72.8-76.6,209903,DB01094,Hesperetin
,18384064,recoveries,"The recoveries of naringenin and hesperetin were 72.8-76.6 and 75.7-77.2%, respectively.",Simultaneous determination of naringenin and hesperetin in rats after oral administration of Da-Cheng-Qi decoction by high-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18384064/),%,75.7-77.2,209904,DB01094,Hesperetin
,32927016,peak plasma concentration (Cmax),"The main metabolites were hesperetin-3'-sulfate with a peak plasma concentration (Cmax) of 80 nmol/L, followed by hesperetin-7-glucuronide (Cmax 24 nmol/L), hesperetin-3'-glucuronide (Cmax 18 nmol/L) and naringenin-7-glucuronide (Cmax 21 nmol/L).",Plasma pharmacokinetics of (poly)phenol metabolites and catabolites after ingestion of orange juice by endurance trained men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32927016/),[nM] / [l],80,210622,DB01094,Hesperetin
,32927016,Cmax,"The main metabolites were hesperetin-3'-sulfate with a peak plasma concentration (Cmax) of 80 nmol/L, followed by hesperetin-7-glucuronide (Cmax 24 nmol/L), hesperetin-3'-glucuronide (Cmax 18 nmol/L) and naringenin-7-glucuronide (Cmax 21 nmol/L).",Plasma pharmacokinetics of (poly)phenol metabolites and catabolites after ingestion of orange juice by endurance trained men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32927016/),[nM] / [l],24,210623,DB01094,Hesperetin
,32927016,Cmax,"The main metabolites were hesperetin-3'-sulfate with a peak plasma concentration (Cmax) of 80 nmol/L, followed by hesperetin-7-glucuronide (Cmax 24 nmol/L), hesperetin-3'-glucuronide (Cmax 18 nmol/L) and naringenin-7-glucuronide (Cmax 21 nmol/L).",Plasma pharmacokinetics of (poly)phenol metabolites and catabolites after ingestion of orange juice by endurance trained men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32927016/),[nM] / [l],18,210624,DB01094,Hesperetin
,32927016,Cmax,"The main metabolites were hesperetin-3'-sulfate with a peak plasma concentration (Cmax) of 80 nmol/L, followed by hesperetin-7-glucuronide (Cmax 24 nmol/L), hesperetin-3'-glucuronide (Cmax 18 nmol/L) and naringenin-7-glucuronide (Cmax 21 nmol/L).",Plasma pharmacokinetics of (poly)phenol metabolites and catabolites after ingestion of orange juice by endurance trained men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32927016/),[nM] / [l],21,210625,DB01094,Hesperetin
,32927016,Cmax,"Among the main phenolic catabolites to increase in plasma after OJ consumption were 3'-methoxycinnamic acid-4'-sulfate (Cmax 19 nmol/L), 3-hydroxy-3-(3'-hydroxy-4'-methoxyphenyl)propanoic acid (Cmax 20 nmol/L), 3-(3'-hydroxy-4'-methoxyphenyl)propanoic acid (Cmax 19 nmol/L), 3-(4'-hydroxyphenyl)propanoic acid (Cmax 25 nmol/L), and 3-(phenyl)propanoic acid (Cmax 19 nmol/L), as well as substantial amounts of phenylacetic and hippuric acids.",Plasma pharmacokinetics of (poly)phenol metabolites and catabolites after ingestion of orange juice by endurance trained men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32927016/),[nM] / [l],19,210626,DB01094,Hesperetin
,32927016,Cmax,"Among the main phenolic catabolites to increase in plasma after OJ consumption were 3'-methoxycinnamic acid-4'-sulfate (Cmax 19 nmol/L), 3-hydroxy-3-(3'-hydroxy-4'-methoxyphenyl)propanoic acid (Cmax 20 nmol/L), 3-(3'-hydroxy-4'-methoxyphenyl)propanoic acid (Cmax 19 nmol/L), 3-(4'-hydroxyphenyl)propanoic acid (Cmax 25 nmol/L), and 3-(phenyl)propanoic acid (Cmax 19 nmol/L), as well as substantial amounts of phenylacetic and hippuric acids.",Plasma pharmacokinetics of (poly)phenol metabolites and catabolites after ingestion of orange juice by endurance trained men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32927016/),[nM] / [l],20,210627,DB01094,Hesperetin
,32927016,Cmax,"Among the main phenolic catabolites to increase in plasma after OJ consumption were 3'-methoxycinnamic acid-4'-sulfate (Cmax 19 nmol/L), 3-hydroxy-3-(3'-hydroxy-4'-methoxyphenyl)propanoic acid (Cmax 20 nmol/L), 3-(3'-hydroxy-4'-methoxyphenyl)propanoic acid (Cmax 19 nmol/L), 3-(4'-hydroxyphenyl)propanoic acid (Cmax 25 nmol/L), and 3-(phenyl)propanoic acid (Cmax 19 nmol/L), as well as substantial amounts of phenylacetic and hippuric acids.",Plasma pharmacokinetics of (poly)phenol metabolites and catabolites after ingestion of orange juice by endurance trained men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32927016/),[nM] / [l],25,210628,DB01094,Hesperetin
,9518163,flow-rate,The flow-rate was 1.0 ml min(-1).,Determination of naringin and naringenin in human urine by high-performance liquid chromatography utilizing solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9518163/),[ml] / [min],1.0,211261,DB01094,Hesperetin
,9518163,signal-to-noise ratio,The lower limits of detection (defined as a signal-to-noise ratio of about 3) were approximately 5 ng for naringin and 1 ng for naringenin.,Determination of naringin and naringenin in human urine by high-performance liquid chromatography utilizing solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9518163/),ng,3,211262,DB01094,Hesperetin
,9518163,signal-to-noise ratio,The lower limits of detection (defined as a signal-to-noise ratio of about 3) were approximately 5 ng for naringin and 1 ng for naringenin.,Determination of naringin and naringenin in human urine by high-performance liquid chromatography utilizing solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9518163/),ng,5,211263,DB01094,Hesperetin
,9518163,signal-to-noise ratio,The lower limits of detection (defined as a signal-to-noise ratio of about 3) were approximately 5 ng for naringin and 1 ng for naringenin.,Determination of naringin and naringenin in human urine by high-performance liquid chromatography utilizing solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9518163/),ng,1,211264,DB01094,Hesperetin
,26254910,absolute bioavailability,"The glucuronides/sulfates were extensively present in the plasma, moreover, the free form was detectable in the plasma, but in a small amount equivalent to nearly 0.85-1.46 % of the amount of glucuronides/sulfates, the absolute bioavailability of MTBH was approximately 31.27 %.",Single Dose Oral and Intravenous Pharmacokinetics and Tissue Distribution of a Novel Hesperetin Derivative MTBH in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26254910/),%,31.27,219218,DB01094,Hesperetin
,33819459,water solubility,HSP was readily encapsulated into RA micelles and this improved its water solubility (to 12.74 mg/mL ± 0.28 mg/mL).,Improved bioavailability and anticancer efficacy of Hesperetin on breast cancer via a self-assembled rebaudioside A nanomicelles system. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33819459/),[mg] / [ml],12.74,221175,DB01094,Hesperetin
,33039389,bioavailable,(Poly)phenols in both beverages were highly bioavailable (between 46 and 59%) and a notable inter-individual variability was seen.,"Absorption, metabolism, and excretion of orange juice (poly)phenols in humans: The effect of a controlled alcoholic fermentation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33039389/),%,46 and 59,228515,DB01094,Hesperetin
,20936271,LODs,"LODs ranged between 15.4 and 107.0 ng mL(-1) and 3.9 and 20.4 ng mL(-1) for flavonoids and isoflavones, respectively.",Analysis of isoflavones and flavonoids in human urine by UHPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20936271/),[ng] / [ml],15.4 and 107.0,231650,DB01094,Hesperetin
,20936271,LODs,"LODs ranged between 15.4 and 107.0 ng mL(-1) and 3.9 and 20.4 ng mL(-1) for flavonoids and isoflavones, respectively.",Analysis of isoflavones and flavonoids in human urine by UHPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20936271/),[ng] / [ml],3.9,231651,DB01094,Hesperetin
,20936271,LODs,"LODs ranged between 15.4 and 107.0 ng mL(-1) and 3.9 and 20.4 ng mL(-1) for flavonoids and isoflavones, respectively.",Analysis of isoflavones and flavonoids in human urine by UHPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20936271/),[ng] / [ml],20,231652,DB01094,Hesperetin
,20936271,Recovery,"Intra-day and inter-day precision (C.V., %) was less than 3.9% and 3.8%, respectively, and accuracy was between 0.03% and 5.0%. Recovery was 70.35-96.58%.",Analysis of isoflavones and flavonoids in human urine by UHPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20936271/),%,70.35,231653,DB01094,Hesperetin
,20100371,Tmax,"The area under the plasma-time curve of naringenin from (2) alpha-rhamnosidase-treated orange juice was increased about 4-fold (P < 0.0001), peak plasma concentration (Cmax) was 5.4-fold higher (P < 0.0001) and Tmax was decreased from 311 to 92 min (P = 0.002) compared to untreated orange juice (1), indicating a change in absorption site from the colon to the small intestine.","Absorption, conjugation and excretion of the flavanones, naringenin and hesperetin from alpha-rhamnosidase-treated orange juice in human subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20100371/),min,311,241413,DB01094,Hesperetin
,20100371,Tmax,"The area under the plasma-time curve of naringenin from (2) alpha-rhamnosidase-treated orange juice was increased about 4-fold (P < 0.0001), peak plasma concentration (Cmax) was 5.4-fold higher (P < 0.0001) and Tmax was decreased from 311 to 92 min (P = 0.002) compared to untreated orange juice (1), indicating a change in absorption site from the colon to the small intestine.","Absorption, conjugation and excretion of the flavanones, naringenin and hesperetin from alpha-rhamnosidase-treated orange juice in human subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20100371/),min,92,241414,DB01094,Hesperetin
,29862124,flow rate,"Analysis was performed on Waters BEH (R) C18 (50 mm × 2.1 mm, 1.7 μm) at a flow rate of 0.2 mL/min by using (A) acetonitrile and (B) 0.5% acetic acid-water as the mobile phase.",Development of an Ultra-High Performance Liquid Chromatography Method for Simultaneous Determination of Six Active Compounds in Fructus aurantii and Rat Plasma and Its Application to a Comparative Pharmacokinetic Study in Rats Administered with Different Doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29862124/),[ml] / [min],0.2,243663,DB01094,Hesperetin
,29862124,extraction recovery,"The RSD of precision ranged from 1.22% to 9.08%, and the average extraction recovery ranged from 96.49 ± 1.42% to 102.01 ± 3.16%.",Development of an Ultra-High Performance Liquid Chromatography Method for Simultaneous Determination of Six Active Compounds in Fructus aurantii and Rat Plasma and Its Application to a Comparative Pharmacokinetic Study in Rats Administered with Different Doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29862124/),%,96.49,243664,DB01094,Hesperetin
,29862124,extraction recovery,"The RSD of precision ranged from 1.22% to 9.08%, and the average extraction recovery ranged from 96.49 ± 1.42% to 102.01 ± 3.16%.",Development of an Ultra-High Performance Liquid Chromatography Method for Simultaneous Determination of Six Active Compounds in Fructus aurantii and Rat Plasma and Its Application to a Comparative Pharmacokinetic Study in Rats Administered with Different Doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29862124/),%,102.01,243665,DB01094,Hesperetin
,30809630,run time,The present method also has a short run time (6.0 min) and easy extraction process.,Simultaneous Determination and Quantitation of Diosmetin and Hesperetin in Human Plasma by Liquid Chromatographic Mass Spectrometry With an Application to Pharmacokinetic Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30809630/),min,6.0,247859,DB01094,Hesperetin
,30809630,relative bioavailability,"On the basis of comparison of the AUC0-t, the relative bioavailability of the test preparation was found 100.94 and 95.09% for diosmetin and hesperitin respectively of that of the reference preparation.",Simultaneous Determination and Quantitation of Diosmetin and Hesperetin in Human Plasma by Liquid Chromatographic Mass Spectrometry With an Application to Pharmacokinetic Studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30809630/),%,100.94,247860,DB01094,Hesperetin
,30809630,relative bioavailability,"On the basis of comparison of the AUC0-t, the relative bioavailability of the test preparation was found 100.94 and 95.09% for diosmetin and hesperitin respectively of that of the reference preparation.",Simultaneous Determination and Quantitation of Diosmetin and Hesperetin in Human Plasma by Liquid Chromatographic Mass Spectrometry With an Application to Pharmacokinetic Studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30809630/),%,95.09,247861,DB01094,Hesperetin
,20125185,urinary excretion,"The study consolidates a significantly lower urinary excretion of quercetin (1.5+/-1%) compared with hesperetin (14.2+/-9.1%) and naringenin (22.6+/-11.5%) and shows that this is not due to a lower bioavailability of quercetin, but rather reflects different clearance mechanisms.","Relative bioavailability of the flavonoids quercetin, hesperetin and naringenin given simultaneously through diet. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20125185/),%,1.5,250038,DB01094,Hesperetin
,20125185,urinary excretion,"The study consolidates a significantly lower urinary excretion of quercetin (1.5+/-1%) compared with hesperetin (14.2+/-9.1%) and naringenin (22.6+/-11.5%) and shows that this is not due to a lower bioavailability of quercetin, but rather reflects different clearance mechanisms.","Relative bioavailability of the flavonoids quercetin, hesperetin and naringenin given simultaneously through diet. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20125185/),%,14.2,250039,DB01094,Hesperetin
,20125185,urinary excretion,"The study consolidates a significantly lower urinary excretion of quercetin (1.5+/-1%) compared with hesperetin (14.2+/-9.1%) and naringenin (22.6+/-11.5%) and shows that this is not due to a lower bioavailability of quercetin, but rather reflects different clearance mechanisms.","Relative bioavailability of the flavonoids quercetin, hesperetin and naringenin given simultaneously through diet. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20125185/),%,22.6,250040,DB01094,Hesperetin
,22883103,flow rate,"Chromatographic separation was performed on a Zorbax SB-C(18) column with the mobile phase of water (containing 0.1% of formic acid)-acetonitrile (30:70, v/v) at a flow rate of 0.3 mL/min in a run time of 7.0 min.",Simultaneous determination of active flavonoids and alkaloids of Tang-Min-Ling-Pill in rat plasma by liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22883103/),[ml] / [min],0.3,251028,DB01094,Hesperetin
,22883103,run time,"Chromatographic separation was performed on a Zorbax SB-C(18) column with the mobile phase of water (containing 0.1% of formic acid)-acetonitrile (30:70, v/v) at a flow rate of 0.3 mL/min in a run time of 7.0 min.",Simultaneous determination of active flavonoids and alkaloids of Tang-Min-Ling-Pill in rat plasma by liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22883103/),min,7.0,251029,DB01094,Hesperetin
,17367568,Cmax,"The Cmax of hesperetin was 43.4 (sd 32.4) and 79.8 (sd 60.1) ng/ml after 150 and 300 ml intake, respectively.",Flavanone plasma pharmacokinetics from blood orange juice in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17367568/),[ng] / [ml],43.4,262999,DB01094,Hesperetin
,17367568,Cmax,"The Cmax of hesperetin was 43.4 (sd 32.4) and 79.8 (sd 60.1) ng/ml after 150 and 300 ml intake, respectively.",Flavanone plasma pharmacokinetics from blood orange juice in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17367568/),[ng] / [ml],79.8,263000,DB01094,Hesperetin
,17367568,plasma peak,For naringenin the plasma peak was 16.4 (sd 11.9) and 34.0 (sd 20.6) ng/ml.,Flavanone plasma pharmacokinetics from blood orange juice in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17367568/),[ng] / [ml],16.4,263001,DB01094,Hesperetin
,17367568,plasma peak,For naringenin the plasma peak was 16.4 (sd 11.9) and 34.0 (sd 20.6) ng/ml.,Flavanone plasma pharmacokinetics from blood orange juice in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17367568/),[ng] / [ml],34.0,263002,DB01094,Hesperetin
